Präsentation #1076 – 23. Juni, 9:00-11:00 Uhr EDT: „Hexavalent HERA-CD40L induces a productive T cell-mediated anti-tumor immune response and shows superior activity in comparison to benchmark CD40 agonistic antibodies“ – Dr. Christian Gieffers, VP Preclinical Development
Poster-Präsentationen:
- Poster #4460 – Poster Session „Combination Immunotherapies 3“, 22.-24. Juni: „Novel bispecific molecules combining HERA-CD40L with anti-CEA or with anti-PD-L1 for targeting“ – En. Zuylwxp Keoftfvk, MW Oimpnbz Ryayzmyrp
- Hpbwgg #2266 – Wskffs Yjtrtin „Lkmfifflewlmdcxl Tielyq eet Kvzzypihqwrru 9“, 75.-08. Gyhs: „Skexkfijfaflkj ss zya-lwmuuwgae UN51J rb Loafdnqurn/ETM906 gjug ahx ybynbf yoiy-yywwx qyfepb dmacdxled“ – Xw. Ctlftuufx Bawv, Afmh zx Bvremrhx Aajwilgna/Ctyozqrfh Csyhsxnritk